Financials Nidan Laboratories and Healthcare Limited
Equities
NIDAN
INE0J6L01013
Healthcare Facilities & Services
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.25 INR | -1.89% |
|
-2.42% | +8.86% |
Valuation
Fiscal Period: March | 2022 | 2023 |
---|---|---|
Capitalization 1 | 461.5 | 470.5 |
Enterprise Value (EV) 1 | 573.4 | 495.6 |
P/E ratio | 14.3 x | 13.3 x |
Yield | - | - |
Capitalization / Revenue | 1.56 x | 1.94 x |
EV / Revenue | 1.93 x | 2.04 x |
EV / EBITDA | 6.1 x | 7.3 x |
EV / FCF | 10,445,419 x | 5,722,616 x |
FCF Yield | 0% | 0% |
Price to Book | 0.66 x | 0.68 x |
Nbr of stocks (in thousands) | 13,900 | 13,900 |
Reference price 2 | 33.20 | 33.85 |
Announcement Date | 8/11/23 | 8/11/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | 206.1 | 221.8 | 207.9 | 296.6 | 242.7 |
EBITDA 1 | 78.45 | 76.36 | 88.87 | 94.06 | 67.9 |
EBIT 1 | 46.09 | 44.48 | 57.02 | 67.83 | 37.05 |
Operating Margin | 22.37% | 20.05% | 27.43% | 22.87% | 15.27% |
Earnings before Tax (EBT) 1 | 2.235 | 7.146 | 33.02 | 45.2 | 48.12 |
Net income 1 | 2.235 | 7.146 | 23.02 | 26.63 | 35.4 |
Net margin | 1.08% | 3.22% | 11.07% | 8.98% | 14.59% |
EPS 2 | 0.2258 | 0.7218 | 2.326 | 2.320 | 2.546 |
Free Cash Flow | - | 5.933 | -30.66 | 54.9 | 86.61 |
FCF margin | - | 2.67% | -14.74% | 18.51% | 35.69% |
FCF Conversion (EBITDA) | - | 7.77% | - | 58.36% | 127.56% |
FCF Conversion (Net income) | - | 83.03% | - | 206.15% | 244.68% |
Dividend per Share | - | - | - | - | - |
Announcement Date | 10/8/21 | 10/8/21 | 10/8/21 | 8/11/23 | 8/11/23 |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | 278 | 270 | 291 | 112 | 25.1 |
Net Cash position 1 | - | - | - | - | - |
Leverage (Debt/EBITDA) | 3.547 x | 3.53 x | 3.275 x | 1.19 x | 0.3698 x |
Free Cash Flow | - | 5.93 | -30.7 | 54.9 | 86.6 |
ROE (net income / shareholders' equity) | - | 6.7% | 18.9% | 6.72% | 5.23% |
ROA (Net income/ Total Assets) | - | 6.3% | 7.3% | 6.02% | 2.68% |
Assets 1 | - | 113.4 | 315.4 | 442.6 | 1,321 |
Book Value Per Share 2 | 10.40 | 11.10 | 13.50 | 50.60 | 50.00 |
Cash Flow per Share 2 | 4.390 | 7.470 | 7.370 | 6.220 | 6.060 |
Capex | - | 0.09 | 32.4 | 70.7 | 6.68 |
Capex / Sales | - | 0.04% | 15.6% | 23.85% | 2.75% |
Announcement Date | 10/8/21 | 10/8/21 | 10/8/21 | 8/11/23 | 8/11/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+8.86% | 6.04M | |
-18.64% | 8.46B | |
+71.50% | 4.41B | |
+11.92% | 2.88B | |
-16.07% | 1.73B | |
-57.49% | 1.7B | |
-16.46% | 1.5B | |
+21.44% | 1.25B | |
-49.06% | 1.03B | |
+16.62% | 968M |
- Stock Market
- Equities
- NIDAN Stock
- Financials Nidan Laboratories and Healthcare Limited